Metagenomi Stock Price, News & Analysis

Metagenomi (Nasdaq: MGX) announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 at 9:30 a.m. GMT.

A live webcast of the presentation will be available in the company's investor section at https://ir.metagenomi.co/, and a replay will be posted there for a limited time.

Metagenomi (Nasdaq: MGX) reported Q3 2025 results and a strategic reprioritization on Nov 11, 2025. The company said new preclinical MGX-001 data demonstrated curative FVIII activity in non-human primates and intends to advance MGX-001 into clinical development.

Management changes: Jian Irish promoted to CEO, Brian Thomas remains on the Board, and Willard Dere named Board Chair. The company reduced headcount by 25% and expects its cash, cash equivalents, and marketable securities of $184.1M as of Sept 30, 2025 to support operations into 4Q 2027. Pre-IND meeting for MGX-001 is expected in 4Q 2025 with IND/CTA submissions targeted in 4Q 2026.

Metagenomi (Nasdaq: MGX) reported preclinical dose‑range data for MGX-001 in hemophilia A showing curative factor VIII (FVIII) activity in non‑human primates and informing a clinical dose strategy. A Pre‑IND meeting is expected in Q4 2025 and IND/CTA submissions are expected by 4Q 2026. Key results: dose‑dependent FVIII activity across AAV and LNP components; at a proposed clinical dose (AAV 5e12 vg/kg + LNP 0.6 mg/kg) average FVIII was 49% (range 29.3%–59.5%); cohort averages reached 49%–81% at higher AAV doses. No animal exceeded 150% FVIII. Treatment was generally well tolerated; transient liver enzyme elevations observed at the highest LNP dose. Orthogonal assays showed no identifiable off‑target editing.

Metagenomi (NASDAQ: MGX), a precision genetic medicines company, reported its Q2 2025 financial results and business updates. The company maintains a strong financial position with $205.0 million in cash and equivalents, expected to fund operations into 2027. Key highlights include progress on their MGX-001 hemophilia A program, where long-term nonhuman primate data showed durable FVIII activity levels through 19 months.

The company presented three abstracts at ASGCT demonstrating proof-of-concept data for compact nucleases and CRISPR-associated transposases (CAST). R&D expenses decreased to $22.5 million from $28.3 million year-over-year, while G&A expenses reduced to $7.0 million from $8.6 million. The company strengthened its leadership by appointing Dr. Laurence Reid to the Board and establishing an R&D Committee.

Metagenomi (NASDAQ: MGX), a precision genetic medicines company, has appointed Dr. Laurence Reid to its Board of Directors. Dr. Reid brings 30 years of experience in building biotech companies and comes with extensive expertise in business development and R&D strategy.

Dr. Reid currently serves as chairperson of Broken String Biosciences Ltd. and holds board positions at KalVista Pharmaceuticals (NASDAQ: KALV) and other private biotech firms. His previous roles include CEO positions at Decibel Therapeutics (acquired by Regeneron in 2023) and Warp Drive Bio (merged with Revolution Medicines in 2018), as well as leadership positions at Alnylam Pharmaceuticals and Millennium Pharmaceuticals.

Metagenomi (Nasdaq: MGX) presented three abstracts at the ASGCT Annual Meeting 2025, showcasing advancements in next-generation genome editing technologies. The company demonstrated significant progress in two key areas: compact nucleases for extrahepatic gene editing and CAST systems for large gene integration. Their MG21-1 nuclease achieved up to 82% protein knockdown in the brain and 71% in the brainstem using single AAV delivery. The ultra-compact MG119-28 nuclease demonstrated 52% editing efficiency in olfactory bulb nuclei and 64% protein knockdown in motor cortex. Additionally, their engineered Type V-K CAST system showed >50x improvement in integration efficiency compared to natural systems, enabling site-specific integration of large therapeutic genes. These developments represent potential breakthroughs for treating neurological disorders and diseases caused by loss-of-function mutations.

Metagenomi (MGX) reported its Q1 2025 financial results and business updates. The company highlighted promising results from its hemophilia A program, demonstrating sustained Factor VIII activity at therapeutically relevant levels over a 19-month study in nonhuman primates. The study showed FVIII activity levels of 80%, 10%, and 32% in three test subjects, correlating with gene integration frequencies. The company maintains a strong financial position with $226.0 million in cash and equivalents, expected to fund operations into 2027. R&D expenses decreased to $25.1 million from $31.4 million in Q1 2024, while G&A expenses reduced to $6.8 million from $8.8 million. Metagenomi also published research in Nature Communications describing novel compact CRISPR-associated transposases (CAST) systems, showcasing their AI-driven metagenomics platform's capabilities.

Metagenomi (Nasdaq: MGX) has announced its participation in two major scientific meetings in May 2025. The company will deliver an oral presentation at TIDES USA 2025 (May 19-22) focusing on AI-guided metagenomic discovery of CRISPR systems for therapeutic genome editing. Additionally, Metagenomi will present three posters at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting (May 13-17), covering topics including in vivo genome editing, site-specific integration of therapeutic transgenes, and CNS gene knockdown via AAV delivery. All presentations will be accessible on the company's investor relations website.

Metagenomi (Nasdaq: MGX) reported its full year 2024 financial results and business updates. The company ended Q4 2024 with $248.3 million in cash and equivalents, providing runway into 2027. Key highlights include sustained Factor VIII activity in nonhuman primate study for hemophilia A program for over 16 months, and advancement of four Wave 1 Ionis targets to lead optimization.

Financial results show R&D expenses increased to $109.2 million in 2024 from $94.4 million in 2023, while G&A expenses rose to $32.0 million from $28.8 million. The company's pipeline achievements include declaring development candidate MGX-001 for hemophilia A, achieving in vivo proof-of-concept across three secreted protein targets, and demonstrating 95% protein knockdown in hypertension studies.

Looking ahead, Metagenomi plans to release final FVIII durability data in H1 2025, file IND submissions in 2026, and nominate 1-2 development candidates from Ionis collaboration programs in 2025.